Connect with us

Marknadsnyheter

Kallak Scoping Study Contract Awarded to SRK Consulting

Published

on

må, okt 09, 2017 08:07 CET

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (”MAR”) (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

For the purposes of MAR and Article 2 of Commission Implementing Regulation (EU) 2016/1055, this announcement is being made on behalf of Kurt Budge, Chief Executive Officer.

9 October 2017

Beowulf (AIM: BEM; Aktietorget: BEO),

the mineral exploration and development company, focused on the Kallak magnetite iron ore project
(“KIOP”)
and the Åtvidaberg polymetallic exploration licence in Sweden, and its graphite portfolio in Finland,
is pleased to announce that it has appointed SRK Consulting (UK) Limited (“SRK”) to complete a Scoping Study on the KIOP.

SRK has already commenced work, and completion of the Scoping Study is scheduled for the end of February 2018.

Kurt Budge, CEO, commented:
 


I am very pleased to be working with SRK on this next phase of Kallak’s development.

“In SRK we have a consultant who has undertaken a significant number of technical studies for companies operating in the Nordic Region, and has the relevant expertise to work with us on designing and engineering a modern and sustainable mining project at Kallak North, as well as assessing the broader potential of the Kallak South deposit.

“The Scoping Study and associated work streams are a significant investment for the Company, made in the belief that Beowulf has satisfied the Swedish requirements to be granted an Exploitation Concession for the Kallak North deposit. In addition, we have the support of local stakeholders and therefore we must push on, despite the current permitting challenges.

“Over the last 12 months, we have continued to emphasise the interlinkages that can exist between major investments, industrial projects and infrastructure development, and the potential for widespread economic stimulus across a region such as Norrbotten, to politicians, regulators, decision makers and stakeholders.  Our project study with Copenhagen Economics, ‘Kallak – A real asset, and a real opportunity to transform Jokkmokk’, is intended to show the ‘Bigger Picture’, and how it can be successfully realised.

“Current experience suggests that major projects are often looked at in isolation, and the interlinkages are not considered, or ignored.  It’s great to see the Inlandsbanan CEO’s comments in the Swedish news last week, where he stated that the railway could be ready and available to take Kallak production, as they are aligned with what we have been saying.

“As we move forward with the Scoping Study, we are looking forward to building stronger collaborations with key infrastructure, commercial, local and regional partners.

“I am excited to be breathing life into the Kallak project, and further demonstrating our commitment to investing in Jokkmokk’s future.  Initiating a Scoping Study is a step we have been waiting to take for almost three years, and it will be great to share with the community, the project development roadmap for advancing Kallak towards production.”

Enquiries:

Continue Reading

Marknadsnyheter

Nordea Bank Abp: Återköp av egna aktier den 31.01.2025

Published

on

By

Nordea Bank Abp
Börsmeddelande – Förändringar i återköpta aktier
31.01.2025 kl. 22.30 EET

Nordea Bank Abp (LEI-kod: 529900ODI3047E2LIV03) har den 31.01.2025 slutfört återköp av egna aktier (ISIN-kod: FI4000297767) enligt följande:

Handelsplats (MIC-kod)

Antal aktier

Viktad snittkurs/aktie, euro*, **

Kostnad, euro*, **

XHEL

132 134

11,54

1 525 249,19

XSTO

104 351

11,55

1 205 344,47

XCSE

25 780

11,54

297 591,60

Summa

262 265

11,55

3 028 185,26

* Växelkurser som använts: SEK till EUR 11,4712 och DKK till EUR 7,4621
** Avrundat till två decimaler

Den 17 oktober 2024 tillkännagav Nordea ett program för återköp av egna aktier till ett värde av högst 250 mn euro med stöd av det bemyndigande som gavs av Nordeas ordinarie bolagsstämma 2024. Återköpet av egna aktier utförs genom offentlig handel i enlighet med Europaparlamentets och rådets förordning (EU) nr 596/2014 av den 16 april 2014 (marknadsmissbruksförordningen) och Kommissionens delegerade förordning (EU) 2016/1052.

Efter de redovisade transaktionerna innehar Nordea 3 287 232 egna aktier för kapitaloptimeringsändamål och 11 513 966 egna aktier för ersättningsändamål.

Uppgifter om respektive transaktion finns som en bilaga till detta meddelande.

För Nordea Bank Abp:s räkning,
Morgan Stanley Europé SE

För ytterligare information:

Ilkka Ottoila, chef för investerarrelationer, +358 9 5300 7058
Mediefrågor, +358 10 416 8023 eller press@nordea.com

Continue Reading

Marknadsnyheter

Qlife comments on the CEO of the company getting a sanction from Finansinspektionen

Published

on

By

The CEO of Qlife Thomas Warthoe has been sanctioned by Finansinspektionen related to insider information.

The sanction relates to an incident in February 2023 when Thomas Warthoe forwarded an email with details related to a rights issue. The e-mail was forwarded to Peter Warthoe, CSO of the company and Thomas’ brother. Peter Warthoe had previously been part of Qlife management but was no longer part of the management at the time of the forwarding. The rights issue was made public later in February 2023.

The information should not have been forwarded and Thomas Warthoe acknowledges his mistake.

“Peter and I have worked together for more than 20 years, and I forwarded this e-mail as a matter of routine. This was a clear mistake, and I should not have forwarded the e-mail. I have decided to accept the sanction, says Thomas Warthoe CEO of Qlife.

Lars Bangsgaard, the chairman of Qlife comments: “It is of course unfortunate that this happens, I am not particularly happy with this or the timing, but my confidence in Thomas Warthoe as CEO remains intact as I regard the issue as a mistake that can happen when you have worked closely together for so many years. We want to leave this behind us and concentrate on the future”.

For more information please contact:

Thomas Warthoe, CEO
tw@egoo.health
+45 21 63 35 34

Qlife is a Swedish company based in Helsingborg, which develops and markets an innovative medical technology platform, Egoo.Health (“Egoo”), with the goal of giving people access to clinical biomarker data when testing at home. The company is listed on the Nasdaq First North Growth Market (ticker: QLIFE). G&W Fondkommission is the Company’s Certified Adviser. For additional information, please visit www.qlifeholding.com.

Continue Reading

Marknadsnyheter

Qlife comments on the CEO of the company getting a sanction from Finansinspektionen

Published

on

By

The CEO of Qlife Thomas Warthoe has been sanctioned by Finansinspektionen related to insider information.

The sanction relates to an incident in February 2023 when Thomas Warthoe forwarded an email with details related to a rights issue. The e-mail was forwarded to Peter Warthoe, CSO of the company and Thomas’ brother. Peter Warthoe had previously been part of Qlife management but was no longer part of the management at the time of the forwarding. The rights issue was made public later in February 2023.

The information should not have been forwarded and Thomas Warthoe acknowledges his mistake.

“Peter and I have worked together for more than 20 years, and I forwarded this e-mail as a matter of routine. This was a clear mistake, and I should not have forwarded the e-mail. I have decided to accept the sanction, says Thomas Warthoe CEO of Qlife.

Lars Bangsgaard, the chairman of Qlife comments: “It is of course unfortunate that this happens, I am not particularly happy with this or the timing, but my confidence in Thomas Warthoe as CEO remains intact as I regard the issue as a mistake that can happen when you have worked closely together for so many years. We want to leave this behind us and concentrate on the future”.

For more information please contact:

Thomas Warthoe, CEO
tw@egoo.health
+45 21 63 35 34

Qlife is a Swedish company based in Helsingborg, which develops and markets an innovative medical technology platform, Egoo.Health (“Egoo”), with the goal of giving people access to clinical biomarker data when testing at home. The company is listed on the Nasdaq First North Growth Market (ticker: QLIFE). G&W Fondkommission is the Company’s Certified Adviser. For additional information, please visit www.qlifeholding.com.

Continue Reading

Trending

Copyright © 2017 Zox News Theme. Theme by MVP Themes, powered by WordPress.